Shield Bio is preventing antibiotic resistance from becoming the leading cause of death worldwide by building the next generation of infectious disease diagnostics. Instead of treating every infection with over-the-top, powerful, broad-spectrum antibiotics, Shield uses genomics to predict the most effective antibiotic for a given infection, allowing safer, cheaper and simpler drugs to be used in most cases and saving our “last line of defense” drugs for only those who truly need them. Shield operates a CLIA/CAP-certified laboratory in San Jose and in 2018 launched their first product: Target-NG, a test for antibiotic resistance in the STD gonorrhea which is now live in clinics across the US. Shield’s current R&D pipeline includes tests for sepsis and hospital acquired infections based on the proprietary Target-X platform. Shield is backed by Andreessen Horowitz, Refactor Capital and Y Combinator and Soma Capital.